Teva settles OxyContin patent lawsuit

August 30, 2006 04:23
1 minute read.


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


Teva Pharmaceutical Industries Ltd., the world's largest generic-drug maker, said it will continue to sell a version of Purdue Pharma Ltd.'s OxyContin painkiller for an undisclosed period after settling a lawsuit. The agreement will end a case in federal court in the southern district of New York and calls for Teva to halt sales at an unspecified date. The accord requires approval of the Federal Trade Commission, the Justice Department and the court, Petah Tikva-based Teva said Tuesday. Last month, Purdue and Endo Pharmaceutical Holdings Inc. reached a settlement in an OxyContin patent dispute that required Endo to stop selling a generic version at the end of the year. In return, Purdue released the company from liability for any infringement of three Purdue patents. Teva said the agreement releases the company from liability. In June 2005, a US appeals court in Washington cleared the way for Endo's generic version by saying Purdue's patents couldn't be enforced because of misrepresentations to the US Patent and Trademark Office. The appeals court later reconsidered its ruling and sent the case back to a federal district court in New York for further review. A finding that the patents were valid and enforceable would have given closely held Purdue the right to seek compensation from Endo for lost sales. Endo said in July it expected oxycodone, the key ingredient in OxyContin, to generate sales of $50 million to $60m. this year. OxyContin, a time-release painkiller prescribed to cancer patients and chronic-pain sufferers, had about $2 billion in sales in 2004. The drug is considered a controlled substance because its potential for abuse is similar to that of morphine, according to Purdue's Web site. (Bloomberg)

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection


Cookie Settings